Acute lymphoblastic leukemia in children

Studying approaches to the treatment of acute lymphoblastic leukemia (ALL) in children is relevant because this oncohematological pathology is the most common in the pediatric population. Modern chemotherapy protocols provide for the differentiated use of cytostatics, taking into account the immunophenotypic and molecular genetic characteristics of tumor cells. This makes it possible to achieve a five-year survival rate of more than 90% of pediatric patients with ALL. However, the ALL forms resistant to chemotherapy, high-risk patients, and relapses force improvements in treatment methods. The above circumstances necessitate a comprehensive analysis of modern scientific data on the treatment of acute lymphoblastic leukemia in children, systematize current data on pathogenetic mechanisms and their impact on the choice of therapeutic tactics, as well as analyze the effectiveness of existing treatment protocols, taking into account the stratification of patients by risk groups and the molecular genetic characteristics of tumor cells. The implementation of the tasks set will make it possible to systematize modern approaches to the treatment of acute lymphoblastic leukemia in children and identify the most promising areas for further research.